vedolizumab
takeda
['vedolizumab', 'ibd', ' vedo', 'vedo', 'crohn']
reprevio presented #ddw2023 prof geert d haens showing vedolizumab prevented postop crohns recurrence 6 months after surgery: 48% were i0. but 23% on vedo &gt;i2b. we will need to assess longer follow up. vedo is a nice option in postop cd prevention 
Professor & Chair, Digestive Disease and Surgery Institute @ClevelandClinic Gastroenterologist in IBD patient-centered care